产品
编 号：F316763
分子式：C17H13Br2N5OS
分子量：495.19
分子式：C17H13Br2N5OS
分子量：495.19
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 315704-66-6
产品详情
生物活性：
PTC-209 is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment.
体内研究：
PTC -209 (60 mg/kg体重；皮下注射；每天一次，持续 11 天) 显著减小肿瘤体积。Animal Model:Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)
Dosage:60 mg/kg body weight
Administration:Subcutaneously; once a day for 11 days
Result:Significantly reduced tumor volume
体外研究：
PTC -209 (0.01-10 μM；24-72 小时) 在所有测试的细胞系中诱导细胞活力的浓度和时间依赖性降低。TC -209 (1-2.5 μM) 抑制 A549 肺癌细胞和 MDA-MB-231 乳腺癌细胞中的 STAT3 磷酸化。
PTC-209 is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment.
体内研究：
PTC -209 (60 mg/kg体重；皮下注射；每天一次，持续 11 天) 显著减小肿瘤体积。Animal Model:Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)
Dosage:60 mg/kg body weight
Administration:Subcutaneously; once a day for 11 days
Result:Significantly reduced tumor volume
体外研究：
PTC -209 (0.01-10 μM；24-72 小时) 在所有测试的细胞系中诱导细胞活力的浓度和时间依赖性降低。TC -209 (1-2.5 μM) 抑制 A549 肺癌细胞和 MDA-MB-231 乳腺癌细胞中的 STAT3 磷酸化。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备